Last reviewed · How we verify
Purified hepatitis B surface antigen
At a glance
| Generic name | Purified hepatitis B surface antigen |
|---|---|
| Sponsor | Bukwang Pharmaceutical |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults (PHASE1)
- Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults (PHASE2)
- Hepatitis B Vaccine Delivered Trans-dermally by MAP (PHASE1)
- Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali (PHASE1)
- Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali (PHASE2)
- Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine (PHASE4)
- Safety and Immunogenicity Following Recombinant Hepatitis B (Bio Farma) Vaccine in Adults & Children (PHASE1)
- Non Inferiority Trial of Locally Manufactured 'Hepa-B' Vaccine in Bangladesh. (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Purified hepatitis B surface antigen CI brief — competitive landscape report
- Purified hepatitis B surface antigen updates RSS · CI watch RSS
- Bukwang Pharmaceutical portfolio CI